POST-MARKETING ADVERSE EVENTS (AES) ASSOCIATED WITH TETRABENAZINE (TBZ): FINDINGS USING FDA'S ADVERSE EVENT REPORTING SYSTEM (FAERS)

被引：0

作者：

Claassen, Daniel O. ^{[1
]}

Iyer, Ravi ^{[2
]}

Dimbil, Mo ^{[3
]}

Giron, Abril ^{[3
]}

De Boer, Lisa ^{[4
]}

Gandhi, Sanjay ^{[2
]}

Hoffman, Keith B. ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Teva Pharmaceut Ind, Frazer, PA USA

[3] Advera Hlth Analyt, Santa Rosa, CA USA

[4] Teva Pharmaceut, La Jolla, CA USA

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2016年 / 87卷

关键词：

D O I：

10.1136/jnnp-2016-314597.206

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

I41

引用

页码：A73 / A73

页数：1

共 50 条

[1] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
Shu-peng Zou
Hai-yun Yang
Meng-ling Ouyang
Qian Cheng
Xuan Shi
Ming-hui Sun
[J]. BMC Pharmacology and Toxicology, 24
[2] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
Zou, Shu-peng
Yang, Hai-yun
Ouyang, Meng-ling
Cheng, Qian
Shi, Xuan
Sun, Ming-hui
[J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
[3] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
Xiong, Xiaomei
Zhang, Xiuwen
Li, Xiaoxia
Huang, Taomin
[J]. EXPERT OPINION ON DRUG SAFETY, 2024,
[4] Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
Zhao, Dan
Zhang, Wangxin
Liu, Yan
Yan, Zhaojun
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[5] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
Wen, Ming-Tao
Li, Jia-Cheng
Lu, Bo-Wen
Shao, Hua-Rong
Ling, Pei-Xue
Liu, Fei
Li, Gang
Luo, Di
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[6] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
Jin, Yiyi
Fan, Miao
Zheng, Xiaomeng
Zhu, Suyan
[J]. EXPERT OPINION ON DRUG SAFETY, 2024,
[7] Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System
Raschi, E.
Fusaroli, M.
Forni, M.
Goldman, A.
Cicero, A. F. G.
Poluzzi, E.
Ponti, F. D.
[J]. DRUG SAFETY, 2022, 45 (10) : 1287 - 1288
[8] Post-marketing safety of checkpoint inhibitors: analysis of the FDA adverse event reporting system
Elias, Rawad
Rider, Jennifer
Rahma, Osama
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[9] Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Michele Fusaroli
Valentina Isgrò
Paola Maria Cutroneo
Carmen Ferrajolo
Valentina Cirillo
Francesca Del Bufalo
Emanuel Raschi
Elisabetta Poluzzi
Gianluca Trifirò
[J]. Drug Safety, 2022, 45 : 891 - 908
[10] Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Fusaroli, Michele
Isgro, Valentina
Cutroneo, Paola Maria
Ferrajolo, Carmen
Cirillo, Valentina
Del Bufalo, Francesca
Raschi, Emanuel
Poluzzi, Elisabetta
Trifiro, Gianluca
[J]. DRUG SAFETY, 2022, 45 (08) : 891 - 908

← 1 2 3 4 5 →